Citius Pharmaceuticals, Inc. (CTXR) Bundle
A Brief History of Citius Pharmaceuticals, Inc. (CTXR)
Foundation and Early Years
Foundation and Early Years
Citius Pharmaceuticals, Inc. was founded in 2015. The company focuses on developing and commercializing therapeutic products in the critical care and oncology sectors. Its headquarters is located in Cranford, New Jersey.
Initial Public Offering
On April 26, 2018, Citius Pharmaceuticals went public through a NASDAQ IPO, raising approximately $16 million by offering 2 million shares at a price of $8.00 per share.
Key Products and Developments
The primary focus of Citius is on its innovative product pipeline, which includes:
- Hydrogel: Designed for use in the treatment of chronic wounds and surgical applications.
- Mino-Lok: An antibiotic lock solution for the treatment of catheter-related bloodstream infections, currently in late-stage clinical trials.
- Citius-101: An investigational drug for acute respiratory distress syndrome (ARDS).
Financial Performance
As of the most recent financial reports for Q3 2023, Citius Pharmaceuticals recorded total assets of approximately $12.5 million and total liabilities of about $3.2 million. The company's net loss for the same quarter was reported to be $2.1 million.
Recent Milestones
In September 2023, Citius announced positive interim results from its ongoing Phase 3 clinical trial for Mino-Lok, leading to an increase in stock price by 45% to a trading value of approximately $2.13 per share.
Market Position and Stock Performance
In October 2023, Citius Pharmaceuticals had a market capitalization of roughly $100 million. The company’s shares have shown volatility, trading in a 52-week range of $1.20 to $4.60.
| Year | IPO Price | Market Cap ($ Million) | Net Loss ($ Million) | Total Assets ($ Million) | Total Liabilities ($ Million) |
|---|---|---|---|---|---|
| 2018 | $8.00 | 25 | N/A | 5.0 | 2.0 |
| 2020 | N/A | 40 | -2.5 | 8.0 | 1.5 |
| 2021 | N/A | 60 | -5.0 | 10.0 | 3.0 |
| 2023 | N/A | 100 | -2.1 | 12.5 | 3.2 |
Future Directions
Citius Pharmaceuticals aims to advance its product pipeline and enhance its market presence through strategic partnerships and research collaborations. The company plans to file for regulatory approval of Mino-Lok in 2024.
A Who Owns Citius Pharmaceuticals, Inc. (CTXR)
Corporate Structure
Citius Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on developing and commercializing therapeutics for patients with critical and life-threatening conditions.
Ownership Breakdown
As of the latest reporting, the ownership structure of Citius Pharmaceuticals, Inc. is divided among institutional investors, retail investors, and company executives. Below are key statistics on the ownership distribution.
| Ownership Type | Percentage Owned | Number of Shares |
|---|---|---|
| Institutional Investors | 35.7% | 27,000,000 |
| Insiders | 10.5% | 7,500,000 |
| Retail Investors | 53.8% | 39,000,000 |
Major Institutional Shareholders
Several institutional investors play a significant role in the ownership of Citius Pharmaceuticals. Below is a table illustrating the largest shareholders.
| Institution Name | Percentage Owned | Number of Shares |
|---|---|---|
| BlackRock, Inc. | 7.2% | 5,200,000 |
| Vanguard Group, Inc. | 5.9% | 4,300,000 |
| J.P. Morgan Asset Management | 4.5% | 3,200,000 |
| Sabby Management, LLC | 3.1% | 2,200,000 |
Insider Ownership
The insider ownership of Citius Pharmaceuticals is comprised of the company’s executives and board members, which includes a mix of stock options and direct shareholdings. Below is a comprehensive list of top insiders and their ownership stakes.
| Insider Name | Position | Shares Owned |
|---|---|---|
| Myron Holubiak | CEO | 2,000,000 |
| Dr. Paul M. Edick | President | 1,500,000 |
| David J. Gelber | CFO | 1,000,000 |
| Michael W. McGowan | Director | 1,000,000 |
Recent Financial Performance
As of the latest financial disclosure, Citius Pharmaceuticals has reported the following key financial figures.
| Financial Metric | Amount |
|---|---|
| Total Revenue (Last Fiscal Year) | $4.5 million |
| Net Income (Loss) | ($10.2 million) |
| Total Assets | $20.1 million |
| Total Liabilities | $15.4 million | Market Capitalization | $150 million |
Recent Stock Performance
The stock price of Citius Pharmaceuticals, Inc. (CTXR) has shown fluctuations over the past year. The following data highlights the stock’s performance metrics.
| Metric | Value |
|---|---|
| Current Stock Price | $1.50 |
| 1-Year High | $3.00 |
| 1-Year Low | $0.80 |
| 52-Week Change | -15% |
Citius Pharmaceuticals, Inc. (CTXR) Mission Statement
Citius Pharmaceuticals, Inc. is committed to advancing innovative therapeutic solutions for critically ill patients. The company's mission is to develop and commercialize innovative therapeutics to address unmet medical needs across various therapeutic areas.
Overview of Citius Pharmaceuticals
Citius Pharmaceuticals focuses on developing critical care therapeutics. As of October 2023, the company is based in New Jersey and is publicly traded. The latest market capitalization is approximately $104 million.
Current Product Pipeline
The product pipeline of Citius Pharmaceuticals includes:
- Hydrogel for Radiation Dermatitis (Mino-Lok®)
- Intravenous Mino-Lok®
- CLX-104 for Advanced Melanoma
Financial Overview
As of Q2 2023, Citius Pharmaceuticals reported:
| Financial Metric | Amount (in $ millions) |
|---|---|
| Revenue | 0.04 |
| Net Loss | 9.52 |
| Total Assets | 31.7 |
| Total Liabilities | 8.6 |
| Cash and Cash Equivalents | 10.2 |
Strategic Goals
The strategic goals for Citius Pharmaceuticals include:
- Advancing clinical trials for Mino-Lok®
- Expanding market reach for new therapies
- Focusing on regulatory approvals
Recent Developments
In August 2023, Citius Pharmaceuticals announced a partnership with a major healthcare provider, aiming to enhance product distribution and accessibility. Additionally, the company is pursuing FDA approvals for its lead products, with projected timelines for submissions in late 2023.
Market Position
Citius Pharmaceuticals operates in a competitive landscape characterized by rapid innovation and regulatory challenges. The company’s market strategy emphasizes:
- Targeting niche therapeutic areas
- Partnerships with established healthcare networks
- Investment in R&D to foster innovation
Conclusion
The mission statement of Citius Pharmaceuticals, Inc. encapsulates the company’s dedication to improving patient outcomes through innovative solutions. With a robust pipeline and a strategic focus on critical care therapeutics, Citius is poised to make significant contributions to the biopharmaceutical landscape.
How Citius Pharmaceuticals, Inc. (CTXR) Works
Overview of Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) is a biopharmaceutical company focused on the development of innovative therapeutics. The company's core therapeutic areas involve oncology, critical care, and other serious medical conditions. Its primary goal is to improve patient outcomes through the advancement of its proprietary product candidates.
Product Pipeline
The product pipeline of Citius Pharmaceuticals includes several key candidates in various stages of development:
| Product Candidate | Indication | Development Stage | Expected Milestones |
|---|---|---|---|
| Mid-Phase 3 Trials of Mino-Lok | Catheter-related bloodstream infections | Late-stage clinical trials | FDA approval expected in Q1 2024 |
| Citius’ Lymphocyte Therapy | Acute myeloid leukemia | Preclinical | Initial data release in 2024 |
| Hydrogel Technology | Various indications | Early-stage research | Research results anticipated in late 2024 |
Financial Performance
As of the last financial report in 2023, Citius Pharmaceuticals posted the following financial data:
| Financial Metric | Amount (2023) |
|---|---|
| Revenue | $1.5 million |
| Net Income (Loss) | $(8.7) million |
| Total Assets | $24.5 million |
| Total Liabilities | $6.2 million |
| Cash and Cash Equivalents | $10.3 million |
| Market Capitalization | $85 million |
Funding and Partnerships
Citius Pharmaceuticals has engaged in various funding activities to support its clinical trials and product development. Key financial events include:
- Public offerings raising approximately $23 million in 2022
- Collaboration agreements with other biotech firms for shared research
- Grants from governmental health agencies for innovative therapies
Regulatory Strategy
Citius Pharmaceuticals employs a strategic approach to regulatory affairs, focusing on compliance with FDA and EMA guidelines. Recent regulatory achievements include:
- Fast Track designation for Mino-Lok
- Orphan drug designation for its Lymphocyte Therapy
- Successful IND submissions for ongoing trials
Market Position and Competitors
The competitive landscape for Citius Pharmaceuticals includes a range of biopharmaceutical companies in similar therapeutic areas. Key competitors consist of:
- Incyte Corporation
- Jazz Pharmaceuticals
- Celgene Corporation
As of 2023, Citius Pharmaceuticals holds a unique position due to its targeted product candidates and innovative approaches in administering therapies.
How Citius Pharmaceuticals, Inc. (CTXR) Makes Money
Product Development
Citius Pharmaceuticals focuses on the development of novel therapeutic products. Their key products include:
- Hydrogel for wound care
- Citius’ flagship product, Mino-Lok, which is an antimicrobial lock solution
- Other investigational products in oncology and critical care
Revenue Streams
The primary sources of revenue for Citius Pharmaceuticals include:
- Product Sales: Revenue generated from the sale of approved therapeutic products.
- Licensing Agreements: Revenue from licensing their technologies to other pharmaceutical companies.
- Partnerships and Collaborations: Joint ventures with larger pharmaceutical companies to co-develop and commercialize products.
Financial Performance
As of the latest financial report (Q2 2023), Citius Pharmaceuticals reported:
- Revenue: $2.1 million
- Net Loss: $6.5 million
- Cash Reserves: $25 million
- Total Assets: $31 million
- Market Capitalization: Approximately $90 million
Research and Development (R&D) Expenses
Citius Pharmaceuticals allocates a significant portion of its budget to R&D. For the year 2022:
| Expense Category | Amount (in millions) |
|---|---|
| Total R&D Expenses | $8.2 |
| Clinical Trial Costs | $4.5 |
| Laboratory Expenses | $1.7 |
| Personnel Costs | $2.0 |
Projected Growth
Market analysts forecast a growth period for Citius Pharmaceuticals, with expectations for the next three years:
| Year | Projected Revenue (in millions) | Projected Net Loss (in millions) |
|---|---|---|
| 2023 | $7.0 | $5.0 |
| 2024 | $15.0 | $3.0 |
| 2025 | $25.0 | $1.0 |
Market Strategy
Citius Pharmaceuticals employs several strategies to enhance their revenue generation:
- Innovation: Continuous investment in R&D for breakthrough therapies.
- Strategic Partnerships: Collaborating with established pharmaceutical companies to leverage their market presence.
- Regulatory Approval Process: Aiming for timely approvals from the FDA for their pipeline products.
Conclusion of Financial Health
Citius Pharmaceuticals remains focused on advancing its clinical programs while managing costs effectively. Their financial health is reflected in their ability to attract investment and sustain operations through strategic development and partnerships.
Citius Pharmaceuticals, Inc. (CTXR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support